Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Debt Ratios
Coverage Ratios
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
Between 2014 and 2018, a consistent increase in leverage and a corresponding decline in solvency margins are observed. The financial structure shifted significantly toward a higher reliance on debt financing, which increased the overall risk profile of the entity's capital base over the five-year period.
- Debt and Capital Structure
- A substantial upward trend is evident across all debt-related ratios. The debt to equity ratio rose from 1.05 in 2014 to 3.29 by 2018, indicating a pivot toward debt-funded growth or obligations. Similarly, the debt to capital ratio increased from 0.51 to 0.77, and the debt to assets ratio climbed from 0.40 to 0.57, confirming that by the end of the period, more than half of the total assets were financed through debt.
- Financial Leverage
- The financial leverage ratio exhibits a sharp increase, rising from 2.66 in 2014 to a peak of 5.76 in 2018. This suggests an aggressive use of debt to amplify potential returns, though it simultaneously increases the vulnerability to interest rate fluctuations and solvency risks.
- Coverage and Debt Servicing Capacity
- The ability to service debt obligations experienced a general decline. The interest coverage ratio dropped from 14.22 in 2014 to 7.52 in 2018, with a notable low of 5.74 in 2016. The fixed charge coverage ratio followed a nearly identical trajectory, falling from 10.77 in 2014 to 6.66 in 2018. Although a temporary recovery in coverage ratios occurred in 2017, the overall trend suggests a diminished margin of safety for meeting fixed financial commitments compared to the start of the analysis period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Debt to Equity
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current portion of long-term debt | 501) | —) | 501) | —) | 606) | |
| Long-term debt, net of discount, excluding current portion | 19,769) | 15,838) | 13,789) | 14,250) | 6,266) | |
| Total debt | 20,270) | 15,838) | 14,289) | 14,250) | 6,872) | |
| Stockholders’ equity | 6,161) | 6,921) | 6,599) | 5,919) | 6,525) | |
| Solvency Ratio | ||||||
| Debt to equity1 | 3.29 | 2.29 | 2.17 | 2.41 | 1.05 | |
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 20,270 ÷ 6,161 = 3.29
2 Click competitor name to see calculations.
An analysis of the solvency position from 2014 to 2018 reveals a significant increase in financial leverage. The primary driver of this trend is a substantial expansion of total debt coupled with relatively stagnant stockholders' equity, resulting in a deteriorating debt to equity profile over the five-year period.
- Total Debt Accumulation
- Total debt grew from 6,872 million US$ in 2014 to 20,270 million US$ by 2018. A sharp escalation occurred between 2014 and 2015, where debt more than doubled to 14,250 million US$. Following a period of relative stability between 2015 and 2017, another significant increase was recorded in 2018, adding approximately 4,432 million US$ to the total obligations.
- Stockholders' Equity Stability
- Stockholders' equity remained comparatively volatile without showing a clear upward trend. From a starting point of 6,525 million US$ in 2014, equity fluctuated, reaching a peak of 6,921 million US$ in 2017 before declining to 6,161 million US$ in 2018. This lack of equity growth suggests that the increase in assets or operations was funded primarily through borrowing rather than retained earnings or capital contributions.
- Debt to Equity Ratio Progression
- The debt to equity ratio reflects a marked increase in financial risk. The ratio rose from 1.05 in 2014 to 3.29 in 2018. A critical jump occurred in 2015, where the ratio shifted to 2.41, indicating a fundamental change in the capital structure. Despite a minor correction to 2.17 in 2016, the ratio trended upward again, culminating in its highest point in 2018, which indicates that total debt was more than triple the amount of shareholders' equity by the end of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Debt to Capital
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current portion of long-term debt | 501) | —) | 501) | —) | 606) | |
| Long-term debt, net of discount, excluding current portion | 19,769) | 15,838) | 13,789) | 14,250) | 6,266) | |
| Total debt | 20,270) | 15,838) | 14,289) | 14,250) | 6,872) | |
| Stockholders’ equity | 6,161) | 6,921) | 6,599) | 5,919) | 6,525) | |
| Total capital | 26,431) | 22,759) | 20,889) | 20,169) | 13,396) | |
| Solvency Ratio | ||||||
| Debt to capital1 | 0.77 | 0.70 | 0.68 | 0.71 | 0.51 | |
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Debt to capital = Total debt ÷ Total capital
= 20,270 ÷ 26,431 = 0.77
2 Click competitor name to see calculations.
Between 2014 and 2018, a consistent upward trend in leverage and total liabilities is evident. The organization shifted from a more balanced capital structure toward a higher reliance on debt financing, as evidenced by the substantial growth in both total debt and the debt-to-capital ratio.
- Total Debt Evolution
- Total debt experienced significant growth, rising from US$ 6,872 million in 2014 to US$ 20,270 million by 2018. The most pronounced increase occurred between 2014 and 2015, where debt more than doubled. Following a period of relative stability in 2016 and 2017, a further sharp increase was recorded in 2018.
- Total Capital Growth
- Total capital increased steadily throughout the period, growing from US$ 13,396 million in 2014 to US$ 26,431 million in 2018. While capital expanded, the rate of growth in total debt outpaced the expansion of the overall capital base, leading to increased financial leverage.
- Debt to Capital Ratio Analysis
- The debt to capital ratio rose from 0.51 in 2014 to 0.77 in 2018. A sharp increase to 0.71 was observed in 2015, indicating a rapid shift in the financing mix. Despite a slight correction to 0.68 in 2016, the ratio trended upward thereafter, peaking at 0.77 in 2018. This progression indicates that by the end of the period, debt constituted a significantly larger portion of the total capital structure than at the beginning.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Debt to Assets
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current portion of long-term debt | 501) | —) | 501) | —) | 606) | |
| Long-term debt, net of discount, excluding current portion | 19,769) | 15,838) | 13,789) | 14,250) | 6,266) | |
| Total debt | 20,270) | 15,838) | 14,289) | 14,250) | 6,872) | |
| Total assets | 35,480) | 30,141) | 28,086) | 27,053) | 17,340) | |
| Solvency Ratio | ||||||
| Debt to assets1 | 0.57 | 0.53 | 0.51 | 0.53 | 0.40 | |
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Debt to assets = Total debt ÷ Total assets
= 20,270 ÷ 35,480 = 0.57
2 Click competitor name to see calculations.
Between 2014 and 2018, a consistent increase in financial leverage is observed, characterized by a substantial rise in both total debt and total assets. The overall solvency profile shifted from a more conservative position in 2014 to a more leveraged state by the end of 2018.
- Total Debt Evolution
- Total debt increased from US$ 6,872 million in 2014 to US$ 20,270 million in 2018. The most significant expansion occurred between 2014 and 2015, where debt more than doubled, followed by a period of relative stability and a further sharp increase in the final year of the period.
- Total Asset Expansion
- Total assets grew from US$ 17,340 million in 2014 to US$ 35,480 million in 2018. This growth pattern closely mirrors the trajectory of total debt, suggesting that a significant portion of asset acquisition and growth was funded through borrowed capital.
- Debt to Assets Ratio Analysis
- The debt to assets ratio rose from 0.40 in 2014 to 0.57 in 2018. Although a slight decrease to 0.51 was recorded in 2016, the long-term trend indicates an increasing reliance on debt to finance the asset base. By 2018, debt financed 57% of total assets, reflecting an increase in financial risk and a higher degree of leverage compared to the 40% recorded at the beginning of the analysis period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Financial Leverage
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | 35,480) | 30,141) | 28,086) | 27,053) | 17,340) | |
| Stockholders’ equity | 6,161) | 6,921) | 6,599) | 5,919) | 6,525) | |
| Solvency Ratio | ||||||
| Financial leverage1 | 5.76 | 4.36 | 4.26 | 4.57 | 2.66 | |
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 35,480 ÷ 6,161 = 5.76
2 Click competitor name to see calculations.
The financial position between 2014 and 2018 is characterized by a substantial expansion of the asset base coupled with a relatively stagnant equity position, resulting in a significant increase in overall financial leverage.
- Asset Growth and Equity Trends
- Total assets experienced a consistent upward trajectory, increasing from US$ 17,340 million in 2014 to US$ 35,480 million by 2018. The most pronounced growth occurred between 2014 and 2015, with assets rising by approximately 56%. In contrast, stockholders' equity exhibited volatility without a clear growth trend, starting at US$ 6,525 million in 2014 and ending at US$ 6,161 million in 2018, remaining effectively flat over the five-year period.
- Financial Leverage Analysis
- A marked increase in financial leverage is observed, indicating a higher reliance on debt or other liabilities to finance growth. The leverage ratio rose sharply from 2.66 in 2014 to 4.57 in 2015. After a period of relative stabilization between 2016 and 2017, where the ratio fluctuated slightly between 4.26 and 4.36, it reached a peak of 5.76 in 2018. This trend confirms that the expansion of the balance sheet was primarily funded through liabilities rather than equity contributions.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Interest Coverage
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income | 4,046) | 2,940) | 1,999) | 1,602) | 2,000) | |
| Add: Income tax expense | 786) | 1,374) | 373) | 422) | 328) | |
| Add: Interest expense | 741) | 522) | 500) | 311) | 176) | |
| Earnings before interest and tax (EBIT) | 5,573) | 4,836) | 2,873) | 2,334) | 2,504) | |
| Solvency Ratio | ||||||
| Interest coverage1 | 7.52 | 9.26 | 5.74 | 7.51 | 14.22 | |
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Interest coverage = EBIT ÷ Interest expense
= 5,573 ÷ 741 = 7.52
2 Click competitor name to see calculations.
The financial trajectory from 2014 to 2018 is characterized by a substantial increase in operational profitability paired with a steady rise in debt servicing costs. While the capacity to meet interest obligations remained strong throughout the period, the interest coverage ratio exhibited significant volatility due to the differing growth rates of earnings and interest expenses.
- Operational Earnings Trend
- Earnings before interest and tax (EBIT) demonstrated a consistent upward trajectory, growing from 2,504 million USD in 2014 to 5,573 million USD in 2018. A notable acceleration in growth occurred between 2016 and 2017, where EBIT increased by approximately 68%, providing a significant cushion for solvency.
- Interest Expense Progression
- Interest expenses rose steadily throughout the observed period, increasing from 176 million USD in 2014 to 741 million USD in 2018. This represents a more than fourfold increase in the cost of debt servicing over the five-year span, indicating an expansion of the company's debt load or an increase in the cost of borrowing.
- Interest Coverage Dynamics
- The interest coverage ratio experienced a sharp decline from 14.22 in 2014 to a low of 5.74 in 2016, reflecting a period where interest expenses grew faster than operational earnings. A recovery was observed in 2017, with the ratio rising to 9.26 due to the surge in EBIT. However, by 2018, the ratio moderated to 7.52, as the continued increase in interest expenses offset a portion of the operational gains.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Fixed Charge Coverage
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income | 4,046) | 2,940) | 1,999) | 1,602) | 2,000) | |
| Add: Income tax expense | 786) | 1,374) | 373) | 422) | 328) | |
| Add: Interest expense | 741) | 522) | 500) | 311) | 176) | |
| Earnings before interest and tax (EBIT) | 5,573) | 4,836) | 2,873) | 2,334) | 2,504) | |
| Add: Rental expense under operating leases | 113) | 69) | 70) | 66) | 62) | |
| Earnings before fixed charges and tax | 5,686) | 4,905) | 2,942) | 2,400) | 2,566) | |
| Interest expense | 741) | 522) | 500) | 311) | 176) | |
| Rental expense under operating leases | 113) | 69) | 70) | 66) | 62) | |
| Fixed charges | 854) | 591) | 570) | 377) | 238) | |
| Solvency Ratio | ||||||
| Fixed charge coverage1 | 6.66 | 8.30 | 5.17 | 6.37 | 10.77 | |
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= 5,686 ÷ 854 = 6.66
2 Click competitor name to see calculations.
The company's capacity to meet its fixed financial obligations exhibits a fluctuating trend characterized by strong overall growth in earnings that was partially offset by a more aggressive increase in fixed charges.
- Earnings before fixed charges and tax
- A significant upward trajectory is observed in earnings, which grew from US$ 2,566 million in 2014 to US$ 5,686 million in 2018. Despite a marginal decline in 2015, the period from 2016 to 2018 was marked by rapid acceleration, with earnings more than doubling from their 2015 low.
- Fixed charges
- Fixed charges experienced a consistent and substantial increase over the five-year period. Obligations rose from US$ 238 million in 2014 to US$ 854 million in 2018, representing a total increase of approximately 258%. The pace of increase in fixed charges outstripped the growth rate of earnings during this timeframe.
- Fixed charge coverage ratio
- The coverage ratio demonstrated volatility, starting at 10.77 in 2014 and declining to a period low of 5.17 in 2016. A temporary recovery occurred in 2017, where the ratio reached 8.30, before moderating to 6.66 by the end of 2018. While the ratio remains well above 1.0, indicating a comfortable margin of safety, the long-term trend reflects a compression of coverage relative to the initial 2014 position.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?